CytoPherx is developing therapies to reduce mortality among patients with acute kidney failure due to a combination of acute kidney injury, sepsis, and/or multi-organ failure.
Recent CytoPherx News
CytoPherx Named "Deal of the Year" by MVCA
CytoPherx Raises $34 Million Early Stage Venture Capital Round
Find Out More About ESP